Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b prospective, single arm, open-label trial determining the efficacy and
feasibility of using a ctDNA assay (test) result to help guide neoadjuvant chemotherapy in
subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal
junction (GEA).